Covid19-Sources

4443 bookmarks
Custom sorting
A circadian based inflammatory response – implications for respiratory disease and treatment | Sleep Science and Practice | Full Text
A circadian based inflammatory response – implications for respiratory disease and treatment | Sleep Science and Practice | Full Text
Circadian clocks regulate the daily timing of many of our physiological, metabolic and biochemical functions. The immune system also displays circadian oscillations in immune cell count, synthesis and cytokine release, clock gene expression in cells and organs of the immune system as well as clock-controlled genes that regulate immune function. Circadian disruption leads to dysregulation of immune responses and inflammation which can further disrupt circadian rhythms. The response of organisms to immune challenges, such as allergic reactions also vary depending on time of the day, which can...
·sleep.biomedcentral.com·
A circadian based inflammatory response – implications for respiratory disease and treatment | Sleep Science and Practice | Full Text
(8) Marcus Ewald auf Twitter: "This is not Kansas anymore. Laut #RKI werden wir auf jeden Fall in der Spitze bei mindestens 25.000 Personen auf der Intensivstation landen. Selbst wenn wir am 05.04. hart locken. Wir sind zu spät. Auch im Best Case. Prognosen im Detail: (1/7) https://t.co/IaZ5zBMg3e" / Twitter
(8) Marcus Ewald auf Twitter: "This is not Kansas anymore. Laut #RKI werden wir auf jeden Fall in der Spitze bei mindestens 25.000 Personen auf der Intensivstation landen. Selbst wenn wir am 05.04. hart locken. Wir sind zu spät. Auch im Best Case. Prognosen im Detail: (1/7) https://t.co/IaZ5zBMg3e" / Twitter
This is not Kansas anymore. Laut #RKI werden wir auf jeden Fall in der Spitze bei mindestens 25.000 Personen auf der Intensivstation landen. Selbst wenn wir am 05.04. hart locken. Wir sind zu spät. Auch im Best Case. Prognosen im Detail: (1/7) pic.twitter.com/IaZ5zBMg3e— Marcus Ewald (@maewald) April 1, 2021
·twitter.com·
(8) Marcus Ewald auf Twitter: "This is not Kansas anymore. Laut #RKI werden wir auf jeden Fall in der Spitze bei mindestens 25.000 Personen auf der Intensivstation landen. Selbst wenn wir am 05.04. hart locken. Wir sind zu spät. Auch im Best Case. Prognosen im Detail: (1/7) https://t.co/IaZ5zBMg3e" / Twitter
Eric Feigl-Ding auf Twitter: "SCHOOL vs COMMUNITY CASES—which comes first? Ontario 🇨🇦 provides clear insights—the general population of Ontario (grey) vs in-school populations of Ontario (yellow). Clearly #COVID19 cases in schools precede any subsequent rise in community. (HT Dr @DGBassani) https://t.co/KwvKZEt6Oh" / Twitter
Eric Feigl-Ding auf Twitter: "SCHOOL vs COMMUNITY CASES—which comes first? Ontario 🇨🇦 provides clear insights—the general population of Ontario (grey) vs in-school populations of Ontario (yellow). Clearly #COVID19 cases in schools precede any subsequent rise in community. (HT Dr @DGBassani) https://t.co/KwvKZEt6Oh" / Twitter
SCHOOL vs COMMUNITY CASES—which comes first? Ontario 🇨🇦 provides clear insights—the general population of Ontario (grey) vs in-school populations of Ontario (yellow). Clearly #COVID19 cases in schools precede any subsequent rise in community. (HT Dr @DGBassani) pic.twitter.com/KwvKZEt6Oh— Eric Feigl-Ding (@DrEricDing) March 31, 2021
·twitter.com·
Eric Feigl-Ding auf Twitter: "SCHOOL vs COMMUNITY CASES—which comes first? Ontario 🇨🇦 provides clear insights—the general population of Ontario (grey) vs in-school populations of Ontario (yellow). Clearly #COVID19 cases in schools precede any subsequent rise in community. (HT Dr @DGBassani) https://t.co/KwvKZEt6Oh" / Twitter
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9uEfficacy:Symptomatic B.1.1.7: 70%; other 82%Asymptomatic B.1.1.7:29%; other 70% pic.twitter.com/oTQX9f9IbQ— Eric Topol (@EricTopol) March 31, 2021
·twitter.com·
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
ARS - Antibiotika Resistenz Surveillance
ARS - Antibiotika Resistenz Surveillance
ARS - Antibiotika-Resistenz-Surveillance: nationales Netzwerk zur Surveillance der Antibiotikaresistenz in Deutschland unter Koordination des Robert Koch-Instituts mit dem Ziel einer repräsentativen flächendeckenden Surveillance der Antibiotikaresistenz in der stationären und ambulanten Krankenversorgung
·ars.rki.de·
ARS - Antibiotika Resistenz Surveillance
outbreak.info
outbreak.info
outbreak.info is a standardized, searchable platform to discover and explore COVID-19 and SARS-CoV-2 data from the Center for Viral Systems Biology (cvisb.org) at Scripps Research. It contains three parts: a standardized searchable database of COVID-19 research; customizable real-time surveillance reports on SARS-CoV-2 variants and mutations; and an explorable interface to examine changes in epidemiological data.
·outbreak.info·
outbreak.info
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine
Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting that the vaccine might reduce infectiousness.
·nature.com·
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine
Diurnal variation in SARS-CoV-2 PCR test results: Test accuracy may vary by time of day | medRxiv
Diurnal variation in SARS-CoV-2 PCR test results: Test accuracy may vary by time of day | medRxiv
False negative tests for SARS-CoV-2 are common and have important public health and medical implications. We tested the hypothesis that the proportion of positive SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) tests varied by time of day, suggesting variation in viral shedding by time of day. Among 30,000 clinical tests performed among symptomatic and asymptomatic patients in the Vanderbilt Affiliated Healthcare Network from March-June 2020, we found evidence for diurnal variation in the proportion of positive SARS-CoV-2 tests, with a peak around 2pm in the afternoon and 2-fold var...
·medrxiv.org·
Diurnal variation in SARS-CoV-2 PCR test results: Test accuracy may vary by time of day | medRxiv
Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 | medRxiv
Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 | medRxiv
As European governments face resurging waves of COVID-19, non-pharmaceutical interventions (NPIs) continue to be the primary tool for infection control. However, updated estimates of their relative effectiveness have been absent for Europe's second wave, largely due to a lack of collated data that considers the increased subnational variation and diversity of NPIs. We collect the largest dataset of NPI implementation dates in Europe, spanning 114 subnational areas in 7 countries, with a systematic categorisation of interventions tailored to the second wave. Using a hierarchical Bayesian tra...
·medrxiv.org·
Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 | medRxiv
RKI - Coronavirus SARS-CoV-2 - Übersicht und Empfehlungen zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC)
RKI - Coronavirus SARS-CoV-2 - Übersicht und Empfehlungen zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC)
Vertreter besorgniserregender Virusvarianten (variants of concern, kurz VOC) wurden weltweit aber auch in Europa, identifiziert. Molekularbiologische Details zu den Varianten sind unter SARS-CoV-2: Virologische Basisdaten und Virusvarianten abrufbar. Die Dynamik der Verbreitung der Varianten in einigen Staaten ist besorgniserregend. Für diese und zukünftig auftretende Virusvarianten gilt, dass sich der Schweregrad der Erkrankung und die Übertragbarkeit im Vergleich gegenüber der initial zirkulierenden Virusvariante möglicherweise verändern können. Weiterhin besteht das Risiko, dass die Wirk...
·rki.de·
RKI - Coronavirus SARS-CoV-2 - Übersicht und Empfehlungen zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC)
Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England | medRxiv
Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England | medRxiv
Background Most individuals with COVID-19 will recover without sequelae, but some will develop long-term multi-system impairments. The definition, duration, prevalence and symptoms associated with long COVID, however, have not been established. Methods Public Health England (PHE) initiated longitudinal surveillance of clinical and non-clinical healthcare workers for monthly assessment and blood sampling for SARS-CoV-2 antibodies in March 2020. Eight months after enrolment, participants completed an online questionnaire including 72 symptoms in the preceding month. Symptomatic mild-to-modera...
·medrxiv.org·
Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England | medRxiv
The emerging plasticity of SARS-CoV-2 | Science
The emerging plasticity of SARS-CoV-2 | Science
Viruses evolve as a result of mutation (misincorporations, insertions or deletions, and recombination) and natural selection for favorable traits such as more efficient viral replication, transmission, and evasion of host defenses. Newly selected traits may be linked in unpredictable ways and raise concern that virus spread and evolution could result in greater virulence (disease severity). The limited diversity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reported during 2020, ascribed to the 3′-5′ exonuclease proofreading function of nonstructural protein 14 (nsp14), le...
·science.sciencemag.org·
The emerging plasticity of SARS-CoV-2 | Science
SARS‐CoV‐2 re‐infection risk in Austria - Pilz - 2021 - European Journal of Clinical Investigation - Wiley Online Library
SARS‐CoV‐2 re‐infection risk in Austria - Pilz - 2021 - European Journal of Clinical Investigation - Wiley Online Library
Background A key question concerning coronavirus disease 2019 (COVID‐19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe ac...
·onlinelibrary.wiley.com·
SARS‐CoV‐2 re‐infection risk in Austria - Pilz - 2021 - European Journal of Clinical Investigation - Wiley Online Library
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter
THREAD1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed)https://t.co/y7l60hqYnf pic.twitter.com/iHSQYC1bT3— Dr Nisreen Alwan 🌻 (@Dr2NisreenAlwan) March 26, 2021
·twitter.com·
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter
Reconciling estimates of global spread and infection fatality rates of COVID‐19: an overview of systematic evaluations - Ioannidis - - European Journal of Clinical Investigation - Wiley Online Library
Reconciling estimates of global spread and infection fatality rates of COVID‐19: an overview of systematic evaluations - Ioannidis - - European Journal of Clinical Investigation - Wiley Online Library
Background Estimates of community spread and infection fatality rate (IFR) of COVID‐19 have varied across studies. Efforts to synthesize the evidence reach seemingly discrepant conclusions. Method...
·onlinelibrary.wiley.com·
Reconciling estimates of global spread and infection fatality rates of COVID‐19: an overview of systematic evaluations - Ioannidis - - European Journal of Clinical Investigation - Wiley Online Library
The infection fatality rate of COVID-19 inferred from seroprevalence data | medRxiv
The infection fatality rate of COVID-19 inferred from seroprevalence data | medRxiv
Objective To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from data of seroprevalence studies. Methods Population studies with sample size of at least 500 and published as peer-reviewed papers or preprints as of July 11, 2020 were retrieved from PubMed, preprint servers, and communications with experts. Studies on blood donors were included, but studies on healthcare workers were excluded. The studies were assessed for design features and seroprevalence estimates. Infection fatality rate was estimated from each study dividing the number of COVID-19 deaths at a...
·medrxiv.org·
The infection fatality rate of COVID-19 inferred from seroprevalence data | medRxiv
Spotlight on the dark figure: Exhibiting dynamics in the case detection ratio of COVID-19 infections in Germany | medRxiv
Spotlight on the dark figure: Exhibiting dynamics in the case detection ratio of COVID-19 infections in Germany | medRxiv
The case detection ratio of COVID-19 infections varies over time due to changing testing capacities, modified testing strategies and also, apparently, due to the dynamics in the number of infected itself. In this paper we investigate these dynamics by jointly looking at the reported number of detected COVID-19 infections with non-fatal and fatal outcomes in different age groups in Germany. We propose a statistical approach that allows us to spotlight the case detection ratio and quantify its changes over time. With this we can adjust the case counts reported at different time points so that...
·medrxiv.org·
Spotlight on the dark figure: Exhibiting dynamics in the case detection ratio of COVID-19 infections in Germany | medRxiv